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What does 
 
The Journal of Experimental
Medicine
 
 look for in a paper? As the
new Executive Editor of the
 
 Journal
 
, I
 
expect to be asked this question repeat-
edly.  The 
 
Journal
 
 is known for its
strengths in specific arenas, including
immunology and inflammation, micro-
bial pathogenesis, oncology, stem cell
 
biology, hematopoiesis, as well as con-
nective tissue and vascular biology.
However, we welcome the submission
of any biomedical research paper that
meets our essential criteria—that is,
the findings must be of broad interest
and provide important insight into the
mechanisms of a pathological process
or potential new approaches to the di-
agnosis, prevention, or treatment of
disease. Biological and physiological
significance has always been empha-
sized in 
 
The JEM
 
, and as one of the
 
Journal’s
 
 new advisors recently said,
“
 
The JEM
 
 has a history of publishing
top quality science, even though it
may not be fashionable. The papers set
trends rather than follow them.”
 
Editorial board
The JEM
 
 is perhaps unusual in that
its 10 academic editors are all located
in three New York City research insti-
tutes:  The Rockefeller University,
Weill Cornell Medical College, and
Memorial Sloan-Kettering Cancer
Center. Not only are these institutes
centers of excellence in diverse areas
of experimental medicine, but also
they are in close proximity, making
possible weekly editorial meetings in
which papers are discussed openly. I
believe this discourse among editors
has been pivotal to 
 
The JEM
 
’s long-
standing position as a leading biomedical
journal. Despite its base in New York,
 
The JEM 
 
is truly international in its
perspective, and I look forward to inter-
acting  with the scientific community
at meetings worldwide.
 
Given that infectious disease remains
 
the single biggest cause of global mor-
bidity and mortality, the cellular and
molecular aspects of host–pathogen
 
interactions are an obvious area of
 
focus for 
 
The JEM.
 
 Remarkable
progress is being made in the fields of
microbial genomics and innate immu-
nity, and we are seeing more and
more groundbreaking work that may
ultimately lead to the development of
new vaccines and therapies targeting
human pathogens. Thus, we are de-
lighted to welcome Dr. Charles Rice
of The Rockefeller University and
Dr. Eric Pamer of Memorial Sloan-
 
Kettering Cancer Center to our edi-
torial board. Drs. Rice and Pamer are
leading figures in the fields of molecular
virology and antimicrobial immunity,
respectively, and will help us con-
 
tinue 
 
The JEM
 
’s
 
 
 
strong tradition in
microbial pathogenesis and immunity
to infection. 
On behalf of the Editors, I would
also like to thank the new, current,
and outgoing members of our advisory
 
board who serve as the 
 
Journal
 
’s primary
referees.
 
Editorial procedures
 
The initial decision whether or not
to send a paper for peer review is
made by the Editors and myself. Many
articles are declined at this stage, not
because they lack scientific merit but
simply because they are not assigned a
high enough priority relative to other
submissions. These manuscripts have
been assessed by at least two Editors.
However, because a judgement based
on priority is inherently subjective, I
regret that we are unable to provide
detailed critiques. Papers not declined
as this stage are sent to external referees
who comment and advise whether the
paper should be declined, accepted, or
returned to the authors for revision.
Over the next few months, I will be
working to ensure that this process is
completed swiftly.
 
Opening up access
 
We want the content of 
 
The JEM
 
to be accessible to as broad an audi-
ence as possible. This month, we are
making online access free to articles 6
months after the publication date. In
the experience of our publisher and
others in the not-for-profit sector,
making primary research papers avail-
able free of charge online 6 months
after their date of publication does
not have a significant impact on reve-
nues from subscriptions. Beginning in
January 2004, 
 
The JEM
 
 will also ex-
tend institutional online access to 142
developing nations at no charge (for a
full list of countries, see http://www.
rupress.org/freeaccess.html). In addi-
tion, we provide reduced subscrip-
tion rates to several countries with
intermediate levels of resources.
Why do we continue to charge
some readers for access to the most
current papers in 
 
The JEM
 
? The alter-
native is completely open access, in
which the costs of publishing are cov-
ered largely by authors or charitable
donations. 
 
The JEM
 
 obtains revenue
from a variety of sources: library and
individual subscriptions, author sub-
mission and page charges, and adver-
tising. By distributing the financial
burden, we ensure that the cost is not
prohibitive for the authors or the
readers. Open access to scientific liter-
ature has, however, become a political
issue (1). Although The Rockefeller
University Press and 
 
The JEM
 
’s Editors
support the various initiatives and ex-
periments aimed at extending open
access, we maintain that these efforts
should be tested and proven to be sus-
tainable financially before journals are
coerced into open access legislation.
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Editorial
 
We take this cautious approach be-
cause it is possible that a highly selec-
tive journal such as 
 
The JEM
 
 could
not run under a system where authors
pay all costs. Relatively nonselective
journals accept, and therefore get
money from, most papers that are sub-
mitted. However, more discriminating
journals must process a large number
of papers, at considerable cost, while
publishing only a few. The author-
pays model would thus yield a small
revenue stream to maintain a more
selective, high quality journal.
What are the potential conse-
quences if subscription-based journals
were forced into open access and then
failed financially? Currently, the interests
of many different organizations are
represented in the scientific literature.
If the diversity of journals was lost, we
would be faced with the unsettling
possibility that one group could control
what scientific data is published and
distributed. Journals are also more
than simply venues for the publication
of data. They act as filters, communica-
tors,  and interpreters, without which
working scientists would be over-
whelmed in a wash of data. Consider
that in 2002 there were 
 
 
 
7,000 articles
published in just one corner of bio-
medical research—the investigation of
the biology and application of stem
cells.
 
*
 
 Stem cell researchers digest this
information by first reading the findings
in a few major journals. Such journals
invest substantial sums of money to
weed through all of the submitted pa-
pers so that only those of the highest
quality and novelty are printed. The
referees in this process work for free,
but the journals pay for the staff which
directs the refereeing, coordinates the
print and online production, and pro-
vides news and commentary.
Based on the commercial reality
that, despite the enormous contribu-
tions of time from academic editors
and referees money is still needed to
run a nonprofit scientific journal, 
 
The
JEM
 
 continues to charge scientists in
certain countries for access to its most
recent articles. We feel 
 
The JEM
 
’s
open access policy is fair, while main-
taining enough financial support from
subscriptions to ensure our continued
existence.
 
On the horizon
 
Excess revenues generated by 
 
The
JEM
 
 are reinvested in the 
 
Journal 
 
to
improve services for our readers and
authors. We are working currently to
provide searchable full-text electronic
access to all 198 volumes of 
 
The JEM
 
,
which date back to 1896. In addition,
pre-1965 abstracts are being added to
the PubMed database. We realize
there are important hypotheses and
conclusions in the older literature that
have considerable relevance to research
today. A striking example in immunol-
ogy is the concept of regulatory T
cells, which first emerged in the 1970s
and was particularly well explored in
 
the context of tumor immunology in
 
The JEM
 
 in the 1980s (see for example
references 2, 3). Unfortunately, diffi-
culty in researching pre–electronic era
literature means that the origins of
current fields of interest are often ig-
nored. Recognizing this problem, 
 
The
JEM
 
 recently added full-text PDFs of
articles dating back to 1975 to its online
archive. Through our website, you
can locate a specific article or browse
issue by issue. In addition, we will
soon be adding a series of tools to our
website that will enable more effective
literature searches. The effort to archive
back to volume 1 issue 1 is ongoing,
and we anticipate that the full 
 
JEM
 
archive will be available online in early
2004. We look forward to greeting the
New Year both by looking back over
 
The JEM
 
’s venerable history and look-
ing forward to its ever brighter future.
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Figure based on a PubMed (http://www4.ncbi.nlm.nih.gov/PubMed) search for articles published in 2002 containing the term “stem cell,” discounting
reviews and editorials.